Skip to content
    MLAB
    Earnings call· Jun 2026(Q1 FY27)

    MESA LABORATORIES INC /CO/ Q1 FY27 earnings call MLAB

    Aug 10, 2026 Source

    Executive summary

    Mesa Laboratories Q1 FY27 — Strong Operational Turnaround and Deleveraging Progress

    Mesa Laboratories delivered a strong operational turnaround in Q1 FY27, with positive organic revenue growth and significant adjusted operating income expansion, driven by improved performance in BPD and other segments. The new CEO emphasized a focus on execution and capital reallocation to high-return businesses, while actively managing the portfolio and committing to full-year guidance in November. Despite SDC's delivery challenges, the underlying demand remains healthy, and the company made substantial progress on deleveraging.

    Highlights

    5

    • Total revenues increased 1% year-over-year to $60.1 million, driven by organic growth.

    • Adjusted operating income (excluding legal settlement) grew 19.5% to $15.4 million, with margin expanding 390 basis points to 25.6% of revenues.

    • Biopharmaceutical Development (BPD) segment grew 5% organically, a significant turnaround from a 30% decline in the prior quarter.

    • Net leverage ratio reduced to 1.85x, with $8.7 million of debt repaid this quarter, moving towards a target of 1.5x to 1.75x by FY27 end.

    • Operating cash flows significantly improved, providing $14.7 million, a $12.8 million year-over-year increase.

    Concerns

    2

    • Sterilization and Disinfection Controls (SDC) reported organic revenue declined 3.6% year-over-year due to delivery reliability issues, with past due backlog increasing by $1 million from year-end.

    • GAAP net income decreased 40.3% to $2.8 million, primarily due to non-cash foreign currency rate changes on an intercompany loan.

    Guidance & targets

    3
    CategoryTargetConfidence
    Full-year FY27 Guidance
    Will be provided
    high materiality
    High
    Biopharmaceutical Development (BPD) Full-Year Growth
    Grow for the full year
    medium materiality
    High
    Net Leverage Ratio
    1.5x to 1.75x
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Sterilization and Disinfection Controls (SDC)
    Revenue decline due to delivery reliability issues, not demand. Underlying demand is healthy. Gross profit percentage decreased due to lower revenues on a partially fixed cost base and product mix. Management is focused on reducing process variability without compromising quality standards to improve delivery.
    Trailing 12-month revenue: $101 millionTrailing 12-month growth: ~5%Past due backlog increase: $1 million (from year-end low)
    		$24.5 million-3.6% organic decline—Gross profit percentage decreased 150 basis points
    Biopharmaceutical Development (BPD)
    Strong organic growth driven by higher immunoassay hardware and consumables volumes and price. Gross profit percentage improved due to a higher mix of immunoassay consumables, supply chain efficiencies, and operating leverage. Management is rebuilding the commercial engine and accelerating the next-generation Gyrolab platform development.
    Immunoassay hardware and consumables volumes: higherNext-generation Gyrolab platform launch: expected FY28
    		$12.1 million5% organically—Gross profit percentage increased 800 basis points
    Calibration Solutions
    Consistent organic growth, contributing steadily to the overall business. Gross profit percentage improved due to higher revenues on a partially fixed cost base.
    		$13.3 million7.6% organically—Gross profit percentage increased 350 basis points
    Clinical Genomics
    Essentially flat revenue, with China declining at a slower rate than last year. Business outside China showed slight growth. Gross profit percentage improved due to price and manufacturing/supply chain efficiency improvements. The business is being managed deliberately with attention to cost structure and returns.
    China revenue decline: 7%Non-China revenue growth: 0.6%
    		$10.3 million-0.1% (essentially flat)—Gross profit percentage increased 790 basis points

    Operational metrics

    13
    Total Revenues
    $60.1 million1% increase compared to prior year
    Q1 FY27

    Total revenues for the first quarter.

    Organic Revenue Growth
    1%
    Q1 FY27

    Non-GAAP organic revenues growth, with no acquisitions over the past 12 months.

    Core Organic Revenue Growth
    0.4%
    Q1 FY27

    Excludes a 60-basis-point tailwind from currency translation, returning Mesa to positive core organic revenues growth.

    Gross Profit Margin
    64.9%Up roughly 290 basis points from 62%
    Q1 FY27

    Gross profit was $39 million or 64.9% of revenues.

    Operating Expenses
    $32 millionDeclined 5.6%
    Q1 FY27

    Operating expenses declined 5.6% to $32 million.

    Adjusted Operating Income (non-GAAP)
    $15 millionIncreased 16.5%
    Q1 FY27

    Non-GAAP adjusted operating income increased 16.5%.

    Adjusted Operating Income (ex-legal settlement)
    $15.4 millionIncreased 19.5%
    Q1 FY27

    Excluding a legal settlement, AOI increased 19.5% to $15.4 million or 25.6% of revenues.

    Trailing 12-Month Adjusted Operating Income (ex-unusual items)
    $66 millionUp about $2.5 million from end of FY26
    TTM

    This figure represents the improvement delivered in the current quarter, swapping last year's first quarter for this one.

    Cash and Cash Equivalents
    $30.7 millionUp from $26.9 million at March 31, 2026
    Q1 FY27 end

    Balance sheet cash position at the end of the quarter.

    Debt Repaid
    $8.7 million
    Q1 FY27

    Amount of debt repaid during the quarter.

    Net Leverage Ratio
    1.85xReduced from prior period
    Q1 FY27 end

    Total net leverage ratio at the end of the quarter.

    Non-Operating Expense Swing
    $2.7 million expenseCompared to $3.9 million income in prior year
    Q1 FY27

    This non-cash item will continue to create quarter-to-quarter volatility.

    Effective Interest Rate
    5.6%
    Q1 FY27

    Current effective interest rate on debt.

    Industry KPIs

    6
    MetricValueDetails
    Revenue EPS guidance—
    China revenue exposureSubstantially lower than $3.5 millionUSD
    Pricing price realization—
    Diagnostics testing demand—
    Segment organic revenue growthSDC: -3.6%; BPD: 5%; Calibration Solutions: 7.6%; Clinical Genomics: -0.1%%
    Instruments vs consumables services mix—

    Product announcements

    1
    ProductTypeDetails
    Next-generation Gyrolab platformroadmap

    Risks & headwinds

    4
    SDC Delivery Reliability IssuesCurrent quarter (Q1 FY27) and ongoing.

    Reported organic revenue down 3.6% YoY; past due backlog up $1 million from year-end low.

    Mitigation: Reducing variability in the process, tightening cycle times without compromising quality standards; SVP of Operations focused on this singular goal.

    Quarterly Volatility from Foreign Currency RatesOngoing, quarter-to-quarter.

    Non-operating expense of $2.7 million in Q1 FY27 compared to non-operating income of $3.9 million in prior year, causing a 40.3% decrease in GAAP net income.

    Mitigation: Acknowledged as a non-cash item primarily due to unrealized currency gains and losses on an intercompany loan, implying it's a reporting volatility rather than an operational cash flow issue.

    China Market HeadwindsOngoing structural issues.

    Clinical Genomics China revenue declined 7%.

    Mitigation: Mesa's revenue exposure to China has declined significantly over the last two years and is now substantially lower than $3.5 million, reducing overall impact. Managing the Clinical Genomics business deliberately with full attention to cost structure and returns.

    Customer Attrition due to Extended DelaysOngoing as long as delivery issues persist.

    Not quantified, but acknowledged that 'extended delays invite customers to evaluate alternatives' and 'I'm not going to promise that has cost us nothing anywhere'.

    Mitigation: Focus on fixing SDC delivery reliability to convert 'surge work into standard work' and ensure customers can count on Mesa.

    What to watch in Q2 FY27

    5

    Full-year FY27 Guidance Release

    November (next earnings call)
    CurrentDirectional commentary provided
    TargetFull-year FY27 guidance

    Why it matters

    The new CEO committed to providing comprehensive full-year guidance, which will outline the company's financial outlook and strategic priorities after his first half-year of data and operational changes.

    As I committed last quarter, we'll provide full year fiscal 2027 guidance at our next earnings call in November, alongside first half results.

    Q&A highlights

    5

    What parts of the business are easiest to build upon, given the historical M&A focus?

    The CEO reiterated that the focus is on execution within the existing portfolio, particularly SDC, BPD, and to an extent Clinical Genomics and Calibration Solutions, rather than M&A. He noted that three of the four businesses are growing nicely with good margin profiles.

    “The near-term value in this company is self-help, executing the businesses we already own, and deliberately reallocating capital, effort, and management mindshare towards the part of the portfolio that offers the most profitable growth.”

    asked by Paul Knight · answered by Siddhartha Kadia

    2 min read5 chapters

    Detailed Narrative

    01

    CEO's First 100 Days and Strategic Focus

    CEO Siddhartha Kadia, in his first earnings call, shared insights from his initial 100 days, emphasizing a direct approach to communication and a focus on execution. He visited every major site, met with over half of employees, and engaged with key customers, concluding that Mesa possesses "durable, regulation-embedded franchises with real and growing earnings power that had fixable execution problems." His immediate focus is on self-help, executing existing businesses, and reallocating capital and management attention to the most profitable growth areas, rather than acquisitions.

    02

    Biopharmaceutical Development (BPD) Turnaround

    The BPD segment demonstrated a significant turnaround, growing 5% organically this quarter after a nearly 30% decline in the previous quarter. While acknowledging easier comparisons and some deferred order catch-up📎, management is actively rebuilding the commercial engine with a new general manager and expects the full commercial transformation to take about a year. The company also reprioritized R&D to accelerate the next-generation Gyrolab platform, now expected to launch in fiscal 2028, signaling a renewed innovation focus.

    03

    Sterilization and Disinfection Controls (SDC) Delivery Challenges

    SDC reported a 3.6% organic revenue decline, attributed to delivery reliability issues rather than a lack of demand. The CEO clarified that past due backlog increased by $1 million from its year-end low, indicating that improvements in throughput were episodic. The core issue stems from maintaining strict quality standards for biological materials, leading to variability in lot clearance times. Management is focused on reducing process variability without compromising quality, aiming for a durable fix to improve customer delivery.

    04

    Balance Sheet Strengthening and Capital Allocation

    Mesa continued to strengthen its balance sheet, repaying $8.7 million of debt and reducing its net leverage ratio to 1.85x. The company aims to further reduce this to 1.5x to 1.75x by the end of FY27. This deleveraging reflects a deliberate priority, with the near-term capital allocation strategy focused on internal execution and optimizing existing businesses, rather than M&A, though small tuck-in acquisitions might be considered later in the year.

    05

    Margin Expansion and Reinvestment Strategy

    The company achieved significant margin expansion, with adjusted operating income (excluding legal settlement) growing 19.5% and margin reaching 25.6% of revenues, a 390 basis point increase. While Q1 is seasonally the lightest volume quarter, management sees an opportunity to reinvest a portion of this operating leverage into faster-growing, higher-return businesses to accelerate growth, rather than solely maximizing current year margins. This strategic reinvestment will be detailed with full-year guidance in November.

    AI-generated summary of the company’s earnings call. Not investment advice.